Net sales surged 82% year-over-year and EBIT loss narrowed by 62%, driven by new contracts and pilots in key industries. Strategic investments and a strong equity ratio position CirChem for continued growth and resilience.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.